Myonecrosis After Revascularization Procedures
Robert M. Califf(Duke Medical Center), E. Magnus Ohman(Duke University), Neal S. Kleiman, Robert A. Harrington(Clinical Research Institute), Richard E. Kuntz(Beth Israel Deaconess Medical Center), Carl J. Pepine(Florida College), Bernard Chaitman(Saint Louis University), Robert P. Bauman(Duke University), Jeffrey J. Popma(MedStar Washington Hospital Center), Ray J. Lipicky(United States Food and Drug Administration), Eric J. Topol(Scripps Research Institute), John A. Bittl(Brigham and Women's Hospital), Barbara E. Tardiff(Duke University), Eric A. Cohen(Sunnybrook Health Science Centre), Charles J. Davidson(Northwestern University), Brian S. Crenshaw(Duke University), Bram D. Zuckerman(United States Food and Drug Administration), Christopher B. Granger(Duke University), Alaa E. Abdelmeguid(Henry Ford Hospital), Kenneth W. Mahaffey(Cardiovascular Institute of the South)
Cited by 553
Related Papers
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
|New England Journal of Medicine|2017|7.7k
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
|European Heart Journal|2012|6.8k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k